Palvella Therapeutics (PVLA) posts corporate presentation — Exhibit 99.1

Palvella Therapeutics, Inc. furnished a Regulation FD disclosure on September 3, 2025 indicating the company has posted a corporate presentation to its website for use in investor meetings.

Rhea-AI Filing Summary

Palvella Therapeutics, Inc. furnished a Regulation FD disclosure on September 3, 2025 indicating the company has posted a corporate presentation to its website for use in investor meetings. The presentation is furnished as Exhibit 99.1 and is incorporated by reference into this report. The filing states the presentation may be used in meetings with investors and clarifies that, except where expressly referenced, the presentation will not be deemed incorporated by reference into other securities filings. The report is signed by Matthew Korenberg, Chief Financial Officer.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Palvella Therapeutics (PVLA) disclose in the 8-K?

The company disclosed it posted a corporate presentation to its website and furnished that presentation as Exhibit 99.1 in a Regulation FD disclosure dated September 3, 2025.

Is the presentation incorporated into other filings for Palvella (PVLA)?

The filing states the presentation is incorporated by reference into this report as Exhibit 99.1 but will not be deemed incorporated by reference into other filings under the Securities Act or the Exchange Act except where expressly stated.

Who signed the 8-K for Palvella Therapeutics (PVLA)?

The 8-K was signed by Matthew Korenberg, Chief Financial Officer.

Where will Palvella use the corporate presentation?

The company said representatives will use the corporate presentation in various meetings with investors from time to time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/03/2025 - 07:31 AM EDT Learn about SEC filing dates

false 0001583648 0001583648 2025-09-03 2025-09-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 3, 2025

PALVELLA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Nevada	001-37471	30-0784346
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

125 Strafford Ave, Suite 360
Wayne, Pennsylvania	19087
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (484) 253-1461

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, $0.001 par value per share		PVLA		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01 Regulation FD Disclosure.

On September 3, 2025, Palvella Therapeutics, Inc. (the “Company”) posted a corporate presentation to its website, which representatives of the Company will use in various meetings with investors from time to time. A copy of the presentation is furnished herewith as Exhibit 99.1, and incorporated herein by reference.

The information furnished pursuant to Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Document
99.1		Corporate Presentation of Palvella Therapeutics, Inc., dated September 3, 2025*
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

*Furnished herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PALVELLA THERAPEUTICS, INC.
Date: September 3, 2025	By:	/s/ Matthew Korenberg
		Matthew Korenberg
		Chief Financial Officer